About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: SCLN
- CUSIP: 80862K10
- Previous Close: $9.85
- 50 Day Moving Average: $10.15
- 200 Day Moving Average: $10.15
- 52-Week Range: $7.51 - $15.02
- Trailing P/E Ratio: 13.93
- Foreward P/E Ratio: 15.08
- P/E Growth: 0.00
- Market Cap: $497.77M
- Outstanding Shares: 51,053,000
- Beta: 1.66
- Net Margins: 23.20%
- Return on Equity: 22.10%
- Return on Assets: 19.47%
Companies Related to SciClone Pharmaceuticals:
- Current Ratio: 7.49%
- Quick Ratio: 6.93%
What is SciClone Pharmaceuticals' stock symbol?
SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."
Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2017?
1 brokers have issued 12 month price targets for SciClone Pharmaceuticals' shares. Their predictions range from $14.00 to $14.00. On average, they anticipate SciClone Pharmaceuticals' share price to reach $14.00 in the next twelve months.
When will SciClone Pharmaceuticals announce their earnings?
SciClone Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
Who owns SciClone Pharmaceuticals stock?
SciClone Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.66%), Renaissance Technologies LLC (3.47%), State Street Corp (2.81%), Stonepine Capital Management LLC (2.45%), Numeric Investors LLC (1.83%) and AQR Capital Management LLC (1.64%). Company insiders that own SciClone Pharmaceuticals stock include Chuncai Meng, Friedhelm Blobel, Hong Zhao, Lan Xie, Nancy T Chang, Richard J Hawkins and Wilson Wai-Shun Cheung.
Who sold SciClone Pharmaceuticals stock? Who is selling SciClone Pharmaceuticals stock?
SciClone Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Oxford Asset Management, Marshall Wace LLP, AQR Capital Management LLC, State Street Corp, Dynamic Technology Lab Private Ltd, Two Sigma Investments LP and Menta Capital LLC. Company insiders that have sold SciClone Pharmaceuticals stock in the last year include Friedhelm Blobel, Nancy T Chang and Wilson Wai-Shun Cheung.
Who bought SciClone Pharmaceuticals stock? Who is buying SciClone Pharmaceuticals stock?
SciClone Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, Guggenheim Capital LLC, Russell Investments Group Ltd., GLG Partners LP, State Board of Administration of Florida Retirement System, Trexquant Investment LP and Bowling Portfolio Management LLC.
How do I buy SciClone Pharmaceuticals stock?
Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of SciClone Pharmaceuticals stock cost?
One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $9.65.